If you’ve been faithfully following your 2.4 mg Wegovy regimen, eating a calorie-reduced diet, and exercising more and still plateaued, the new 7.2 mg dose could help you break through.
Wegovy, a brand name for the medicine semaglutide, is a once-weekly GLP-1 receptor agonist injection approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition. It works by mimicking a natural gut hormone to curb appetite, slow gastric emptying, and support sustainable calorie control when combined with a reduced-calorie diet and increased physical activity.
On March 19, 2026, the FDA approved the higher 7.2 mg dose, branded as Wegovy HD, under the fast-track National Priority Voucher program, only 54 days after filing. Wegovy HD will be administered weekly by injection.
Novo Nordisk increased the Wegovy dose because, despite the effectiveness of the 2.4 mg dose, some people still don’t achieve their therapeutic goals.
According to findings from the STEP UP clinical studies, switching to this higher maintenance dose can result in significantly more weight loss for many people than the standard 2.4 mg dose.
Read on to learn everything you need to know about Wegovy HD, what it is, what the data shows, and safety considerations.
What Is Wegovy and How Does It Work?
Wegovy is a once-weekly GLP-1 receptor agonist injection approved for chronic weight management in adults and adolescents with obesity or overweight when paired with diet and exercise.
The Wegovy injection is also approved to help reduce the risk of major cardiovascular events in some people with obesity or who are overweight and for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Wegovy is available as a pre-filled injector pen. You can inject it yourself under your skin in your buttocks, upper arms, stomach, or thighs every week.
Wegovy is also available in pill form, which is taken once daily every morning with water, no more than 4 ounces (½ cup) of plain water. Wegovy pills should be swallowed whole and should not be crushed, split, chewed, or dissolved.
Wegov works by mimicking a natural gut hormone called glucagon-like peptide-1 (GLP-1), a natural hormone released in the body after eating. GLP-1 helps reduce appetite, promote feelings of fullness, slow gastric emptying so food stays in your stomach longer, and support better blood sugar regulation.
Both Wegovy pills and injections should be paired with a reduced-calorie diet and increased physical activity to promote weight management and overall well-being.
Wegovy injections are started at a low weekly dose and progressively increased over several months to help the body adjust to the drug. The starting dose is 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg, then the standard maintenance dose of 2.4 mg.
If your body tolerates the 2.4 mg dose, your dosage may be increased to the now FDA-approved 7.2 mg subcutaneously once weekly for at least 4 weeks.
What Is Wegovy HD: The New Higher Dose?
Wegovy HD is a new semaglutide injection administered subcutaneously once a week at a strength of 7.2 milligrams. It was approved by the FDA on March 19, 2026, for adults with obesity or overweight with at least one weight-related condition. Like the standard dose, it is meant to be used alongside a reduced-calorie diet and increased physical activity.
For now, the 7.2 mg dose is administered by injecting three 2.4 mg pens at the same time each week. The injections can be administered in the same body part, but should be spaced at least 5 cm apart. You may need to use more than one pen, and you must replace the needle after each dose.
A single 7.2 mg pen is expected to become available in April. More details on coverage and savings options, including other initiatives to lower out-of-pocket expenses, will be available in that timeframe.
Before moving up to the 7.2 mg dosage, you must complete at least four weeks on the standard 2.4 mg maintenance dose to ensure your body tolerates the medication well.
Here is the full dosing schedule:
| Weeks | Weekly Dose |
| 1–4 (Starting dose) | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17+ | 2.4 mg (standard maintenance) |
| 21+ (if needed) | 7.2 mg (new higher maintenance) |
How Effective Is Wegov HD?
Wegovy HD is highly effective for chronic weight management, demonstrating an average weight reduction of approximately 21% at 72 weeks in trials, with some participants losing 25% or more.
The most compelling evidence for the new 7.2 mg dose comes from the STEP UP phase 3b clinical trial. This randomized, double-blind study followed more than 1,000 adults living with obesity (but without type 2 diabetes) for 72 weeks. Participants received either Wegovy HD 7.2 mg, the standard 2.4 mg dose, or placebo, all while following a reduced-calorie diet and increased physical activity.
Among people taking Wegovy HD, 93.2% achieved 5% or more body weight loss, compared with 35.7% taking a placebo.
Adults with obesity taking Wegovy 7.2 milligrams lost about 20.7%–21% of their body weight on average, versus 17.5% on those taking the 2.4 mg dose and only 2.4% on placebo. About 1 in 3 patients achieved at least 25% weight loss.
Beyond the scale, data from related studies indicate additional cardiometabolic improvements, including meaningful reductions in waist circumference and better blood pressure control, key markers of long-term heart health.
Overall, the STEP UP results confirm that the new 7.2 mg dose can deliver significantly greater weight loss for the right patients.
Who should use Wegovy HD?
The ideal candidates for Wegov HD are adults with obesity or overweight with at least one weight-related condition who have already completed at least four weeks on the 2.4 mg maintenance dose, tolerate it well, and have either plateaued or want additional weight-loss progress.
Wegovy HD is not suitable for everyone. It is not recommended if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, or severe gastrointestinal disorders. People who cannot tolerate the 2.4 mg dose due to side effects should not escalate.
Do I Still Need to Diet and Exercise with Wegovy HD?
Yes, and the results are even better when you do. Wegovy HD is FDA-approved as an adjunct treatment, meaning it works alongside a reduced-calorie diet and increased physical activity, not instead of them.
In the STEP UP trial and all previous STEP studies, every participant who achieved an average weight loss of 20–21% was following a structured lifestyle plan. The medication reduces hunger, quiets food noise, and helps you feel full longer, but the calorie deficit and exercise are what turn those effects into lasting fat loss and improved health.
What Are the Side Effects of Wegovy HD?
Wegovy HD has a safety profile similar to the standard 2.4 mg dose, with most side effects mild to moderate and improving as your body adjusts. Because it is a higher dose, some side effects occur a bit more frequently, but they are generally manageable with the right support.
Most common side effects include:
- Gastrointestinal issues: Nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These were reported by about 71% of patients on 7.2 mg compared with 61% on 2.4 mg. They usually peak during the first few weeks after dose escalation and tend to lessen over time.
- Skin sensations (dysesthesia): Feelings of sensitivity, burning, tingling, or pain on the skin, seen in 22–23% of people on the higher dose versus about 6% on 2.4 mg. Most cases are mild and resolve without stopping treatment.
Serious side effects are rare and similar to those of lower-dose Wegovy. They can include inflammation of the pancreas, gallbladder problems, severe allergic reactions, or low blood sugar, especially when taken with certain diabetes medicines.
Wegovy carries a boxed warning for the possible risk of thyroid C-cell tumors, seen in animal studies but not confirmed in humans. It is not recommended if you have a history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, or pancreatitis.
How to Get Higher-Dose Wegovy
Getting started with higher-dose semaglutide through NP2GO is simple, fast, and designed with your convenience in mind.
Here’s how it works:
- Schedule your virtual weight-loss visit: Book online in minutes for just $99 (billed every 3 months). You’ll meet privately with a board-certified nurse practitioner from the comfort of your home.
- Get a personalized evaluation: Your provider will review your full medical history; current Wegovy progress, including how well you tolerated the 2.4 mg dose; lab results, if needed; and your weight loss goals. If you’re a good candidate, they can prescribe the 7.2 mg dose immediately.
- Receive your prescription and start: We’ll then send the prescription to a pharmacy that carries Wegovy HD. Because the higher dose is newly approved, our team stays on top of real-time pharmacy stock and will guide you to the fastest option available.
- Ongoing support: You will need regular follow-up visits, lifestyle coaching, tips for managing side effects, and adjustments as needed.
FAQs About the Higher Dose of Wegovy
Do you lose more weight on Wegovy HD?
Yes. In the STEP UP clinical trial, patients on Wegovy HD lost an average of 20.7–21% of their body weight over 72 weeks, compared to 17.5% on the 2.4 mg dose. This means a higher chance of achieving 20% or even 25% total weight loss. Individual results vary based on diet, exercise, and adherence.
What are the higher-dose Wegovy side effects?
Wegovy HD has a similar side effect profile to the standard dose. The most common are gastrointestinal issues affecting about 71% of users. Skin sensations like tingling or burning (dysesthesia) are more frequent at the higher dose. Most side effects are mild and temporary and improve over time.
When to increase the Wegovy dose?
Consider increasing to the 7.2 mg dose only after staying on the standard 2.4 mg maintenance dose for at least 4 weeks, provided you tolerate it well. Your NP2GO provider will recommend the higher dose if you’ve hit a plateau or need more weight-loss progress while continuing diet and exercise.
When will the single 7.2 mg pen be available?
The single 7.2 mg Wegovy pen is expected to become available in April. Right now, the 7.2 mg dose requires injecting three 2.4 mg pens weekly.
Conclusion
The FDA approval of Wegovy HD is an exciting milestone in the treatment of obesity, providing a proven option for achieving even greater, clinically significant weight loss when the standard dose isn’t enough.
With impressive results from the STEP UP trial and a safety profile consistent with lower doses, this higher maintenance dose could be the key to breaking through plateaus and reaching your goals.
At NP2GO, we specialize in personalized GLP-1 treatment plans. We stay current with the latest approvals, such as Wegovy HD, and provide convenient virtual care, ongoing monitoring, and comprehensive support tailored to your unique health journey.
Ready to see if the new higher-dose Wegovy is right for you? Schedule your virtual weight-loss consultation today for just $99. Take the next step toward transformative results with expert guidance every step of the way.